Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Oncology Consultants Oncology Consultants, P.A.
mi
from
Houston, TX
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Oncology Consultants Oncology Consultants, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Oregon Health and Science University
mi
from
Portland, OR
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Pacific Cancer Medical Center
mi
from
Anaheim, CA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Providence Regional Cancer Partnership
mi
from
Everett, WA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Providence Regional Cancer Partnership
mi
from
Everett, WA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer
mi
from
Burbank, CA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer
mi
from
Burbank, CA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
St. Jude Heritage Medical Group Virginia Crosson Cancer Center
mi
from
Yorba Linda, CA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
St. Jude Heritage Medical Group Virginia Crosson Cancer Center
mi
from
Yorba Linda, CA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
St. Louis University Cancer Center
mi
from
St. Louis, MO
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
St. Louis University Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Stroger Cook County Hospital Division of Hematology & Onc
mi
from
Chicago, IL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Stroger Cook County Hospital Division of Hematology & Onc
mi
from
Chicago, IL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Tennessee Oncology Sarah Cannon Research Inst.
mi
from
Nashville, TN
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Tennessee Oncology Sarah Cannon Research Inst.
mi
from
Nashville, TN
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
The Jones Clinic, PC
mi
from
Germantown, TN
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
University of Nebraska Medical Center University of Nebraska Med Ctr
mi
from
Omaha, NE
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
University of Nebraska Medical Center University of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
University of Virginia
mi
from
Charlottesville, VA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Sarah Cannon Research Institute SCRI
mi
from
Jacksonville, FL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Sarah Cannon Research Institute SCRI
mi
from
Jacksonville, FL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Pasco Hernando Oncology
mi
from
New Port Richey, FL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Pasco Hernando Oncology
mi
from
New Port Richey, FL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
University of Maryland
mi
from
Baltimore, MD
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
University of Rochester Medical Ct James P Wilmot Cancer Ctr
mi
from
Rochester, NY
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
University of Rochester Medical Ct James P Wilmot Cancer Ctr
mi
from
Rochester, NY
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
mi
from
Chattanooga, TN
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma
Status: Enrolling
Updated:  1/11/2016
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma
Status: Enrolling
Updated: 1/11/2016
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma
Status: Enrolling
Updated:  1/11/2016
Albert Einstein College of Medicine
mi
from
Bronx, NY
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma
Status: Enrolling
Updated: 1/11/2016
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma
Status: Enrolling
Updated:  1/11/2016
NYU Cancer Institute
mi
from
New York, NY
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma
Status: Enrolling
Updated: 1/11/2016
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma
Status: Enrolling
Updated:  1/11/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma
Status: Enrolling
Updated: 1/11/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Phase II Subcutaneous VELCADE and Oral Cyclophosphamide-based Induction + Sequential VELCADE and Revlimid Maintenance for Newly Diagnosed Multiple Myeloma in Non-transplant Candidates: An Entirely Non-intravenous Regimen
Status: Enrolling
Updated:  1/11/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Phase II Subcutaneous VELCADE and Oral Cyclophosphamide-based Induction + Sequential VELCADE and Revlimid Maintenance for Newly Diagnosed Multiple Myeloma in Non-transplant Candidates: An Entirely Non-intravenous Regimen
Status: Enrolling
Updated: 1/11/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Pilot Clinical Study of GCSF in Combination With Desipramine for Autologous Stem Cell Mobilization in Multiple Myeloma
Status: Enrolling
Updated:  1/11/2016
Albert Einstein College of Medicine
mi
from
Bronx, NY
Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Pilot Clinical Study of GCSF in Combination With Desipramine for Autologous Stem Cell Mobilization in Multiple Myeloma
Status: Enrolling
Updated: 1/11/2016
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age
Status: Enrolling
Updated:  1/11/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age
Status: Enrolling
Updated: 1/11/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Teramana Cancer Center
mi
from
Steubenville, OH
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Teramana Cancer Center
mi
from
Steubenville, OH
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Beaver
mi
from
Beaver, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Beaver
mi
from
Beaver, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Jefferson
mi
from
Clairton, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Jefferson
mi
from
Clairton, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Arnold Palmer at Mountain View
mi
from
Greensburg, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Arnold Palmer at Mountain View
mi
from
Greensburg, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Arnold Palmer at Oakbrook
mi
from
Greensburg, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Arnold Palmer at Oakbrook
mi
from
Greensburg, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Indiana
mi
from
Indiana, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Indiana
mi
from
Indiana, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Johnstown
mi
from
Johnstown, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Johnstown
mi
from
Johnstown, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
Hematology-Oncology Associates of UPCI
mi
from
McKeesport, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
Hematology-Oncology Associates of UPCI
mi
from
McKeesport, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
Hematology/Oncology - Private Practice
mi
from
McKeesport, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
Hematology/Oncology - Private Practice
mi
from
McKeesport, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Monroeville
mi
from
Monroeville, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Monroeville
mi
from
Monroeville, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Arnold Palmer at Mt. Pleasant
mi
from
Mt. Pleasant, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Arnold Palmer at Mt. Pleasant
mi
from
Mt. Pleasant, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - New Castle
mi
from
New Castle, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - New Castle
mi
from
New Castle, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - St. Margaret's
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - St. Margaret's
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers, Hillman Cancer Center
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers, Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Passavant
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Passavant
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
VA Healthcare System - 646
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
VA Healthcare System - 646
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Drake
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Drake
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Uniontown
mi
from
Uniontown, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Uniontown
mi
from
Uniontown, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Washington
mi
from
Washington, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Washington
mi
from
Washington, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - North Hills
mi
from
Wexford, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - North Hills
mi
from
Wexford, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Windber
mi
from
Windber, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Windber
mi
from
Windber, PA
Click here to add this to my saved trials
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated:  1/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated: 1/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
A Myeloablative Conditioning Regimen Consisting of Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients With Hematological Malignancy.
Status: Enrolling
Updated:  1/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
A Myeloablative Conditioning Regimen Consisting of Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients With Hematological Malignancy.
Status: Enrolling
Updated: 1/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)
Status: Enrolling
Updated:  1/14/2016
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)
Status: Enrolling
Updated: 1/14/2016
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
HD Melphalan and SCT in Patients With IGDD or LCDD
High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT) in Light-Chain Deposition Disease (LCDD) and Immunoglobulin Deposition Disease (IGDD)
Status: Enrolling
Updated:  1/14/2016
Boston University Cancer Research Center
mi
from
Boston, MA
HD Melphalan and SCT in Patients With IGDD or LCDD
High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT) in Light-Chain Deposition Disease (LCDD) and Immunoglobulin Deposition Disease (IGDD)
Status: Enrolling
Updated: 1/14/2016
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials